Q1 Earnings Forecast for Sanofi Issued By Leerink Partnrs

Sanofi (NASDAQ:SNY) – Stock analysts at Leerink Partnrs raised their Q1 2025 earnings per share (EPS) estimates for Sanofi in a report released on Sunday, March 30th. Leerink Partnrs analyst D. Risinger now expects that the company will earn $0.88 per share for the quarter, up from their previous estimate of $0.85. The consensus estimate for Sanofi’s current full-year earnings is $4.36 per share. Leerink Partnrs also issued estimates for Sanofi’s Q2 2025 earnings at $0.93 EPS, Q3 2025 earnings at $1.64 EPS, Q4 2025 earnings at $0.94 EPS, FY2025 earnings at $4.39 EPS, FY2026 earnings at $5.00 EPS, FY2027 earnings at $5.03 EPS, FY2028 earnings at $5.49 EPS and FY2029 earnings at $6.02 EPS.

Other equities analysts have also issued research reports about the stock. The Goldman Sachs Group initiated coverage on shares of Sanofi in a report on Friday, March 21st. They issued a “neutral” rating and a $65.00 price target for the company. Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. StockNews.com downgraded Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Finally, Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Three investment analysts have rated the stock with a hold rating, one has given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Sanofi currently has an average rating of “Moderate Buy” and an average price target of $62.50.

Sanofi Stock Down 2.0 %

Shares of NASDAQ:SNY opened at $54.34 on Tuesday. The company has a 50 day moving average price of $55.28 and a two-hundred day moving average price of $52.73. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46. The company has a market capitalization of $137.91 billion, a PE ratio of 21.82, a PEG ratio of 1.01 and a beta of 0.58. Sanofi has a 52 week low of $45.22 and a 52 week high of $60.12.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%.

Hedge Funds Weigh In On Sanofi

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Synergy Asset Management LLC bought a new stake in shares of Sanofi in the fourth quarter valued at about $25,000. McClarren Financial Advisors Inc. lifted its stake in Sanofi by 952.6% in the 4th quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock valued at $28,000 after acquiring an additional 543 shares in the last quarter. Lee Danner & Bass Inc. bought a new position in shares of Sanofi during the 4th quarter worth approximately $31,000. Bessemer Group Inc. raised its holdings in shares of Sanofi by 59.8% in the fourth quarter. Bessemer Group Inc. now owns 647 shares of the company’s stock valued at $32,000 after purchasing an additional 242 shares during the last quarter. Finally, Sunbelt Securities Inc. raised its holdings in shares of Sanofi by 72.1% in the third quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock valued at $43,000 after purchasing an additional 313 shares during the last quarter. 14.04% of the stock is owned by institutional investors and hedge funds.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.